Intrexon Corporation (NYSE:XON) has been given an average rating of “Hold” by the eight brokerages that are presently covering the firm, Marketbeat reports. Two research analysts have rated the stock with a sell rating, one has issued a hold rating and five have given a buy rating to the company. The average 1 year price target among brokers that have issued ratings on the stock in the last year is $38.50.
A number of research firms have commented on XON. Northland Securities set a $30.00 price target on shares of Intrexon and gave the stock a “buy” rating in a report on Monday, August 7th. BidaskClub cut shares of Intrexon from a “sell” rating to a “strong sell” rating in a report on Tuesday, August 22nd. JMP Securities reiterated an “outperform” rating and set a $42.00 price objective on shares of Intrexon in a report on Thursday, October 5th. Griffin Securities reiterated a “buy” rating and set a $55.00 price objective on shares of Intrexon in a report on Friday, October 6th. Finally, Bank of America reduced their price objective on shares of Intrexon from $25.00 to $21.00 and set a “neutral” rating for the company in a report on Friday, November 10th.
Institutional investors have recently added to or reduced their stakes in the stock. Tower Research Capital LLC TRC boosted its holdings in Intrexon by 2,031.7% during the second quarter. Tower Research Capital LLC TRC now owns 5,180 shares of the biotechnology company’s stock worth $125,000 after purchasing an additional 4,937 shares during the last quarter. Steward Partners Investment Advisory LLC purchased a new position in Intrexon during the third quarter worth about $121,000. Federated Investors Inc. PA purchased a new position in Intrexon during the second quarter worth about $172,000. SG Americas Securities LLC purchased a new position in Intrexon during the third quarter worth about $139,000. Finally, Principal Financial Group Inc. purchased a new position in Intrexon during the second quarter worth about $212,000. Institutional investors and hedge funds own 77.49% of the company’s stock.
WARNING: “Intrexon Corporation (XON) Receives $38.50 Average Price Target from Brokerages” was first posted by Chaffey Breeze and is owned by of Chaffey Breeze. If you are viewing this report on another domain, it was illegally copied and reposted in violation of U.S. & international copyright & trademark legislation. The correct version of this report can be read at https://www.chaffeybreeze.com/2017/12/05/intrexon-corporation-xon-receives-38-50-average-price-target-from-brokerages.html.
Intrexon Corporation (Intrexon) forms collaborations to create biologically-based products and processes using synthetic biology. The Company’s domestic operations are in California, Florida, Maryland, and Virginia, and its primary international operations are in Belgium and Hungary. The Company designs, builds and regulates gene programs, which are deoxyribonucleic acid (DNA) sequences that consist of genetic components.
Receive News & Ratings for Intrexon Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intrexon Corporation and related companies with MarketBeat.com's FREE daily email newsletter.